amifostine anhydrous has been researched along with gemcitabine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Pronk, LC; Schellens, JH; Verweij, J | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Crane, CH; Janjan, NA; Mason, KA; Milas, L; Phan, TP; Vrdoljak, E | 1 |
| Aydin, F; Ilis, E; Ozdemir, F; Yavuz, AA; Yavuz, MN | 1 |
| Senzer, N | 1 |
| de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB | 1 |
| Haigentz, M; Hamilton, A; Hochster, H; Kim, M; Lee, J; Macapinlac, M; Mirchandani, D; Muggia, FM; Pavlick, A; Sewak, S; Sorich, J; Volm, M | 1 |
| Altug, T; Atalar, B; Dinçbaş, FO; Gedik, N; Ilvan, S; Koca, S; Oksüz, DC; Ozel, S | 1 |
2 review(s) available for amifostine anhydrous and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; Indoles; Neoplasms; Organoplatinum Compounds; Paclitaxel; Protein Kinase C; Topoisomerase I Inhibitors | 1996 |
3 trial(s) available for amifostine anhydrous and gemcitabine
| Article | Year |
|---|---|
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Analysis; Thrombocytopenia; Vomiting | 2001 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytoprotection; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms | 2003 |
5 other study(ies) available for amifostine anhydrous and gemcitabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment.
Topics: Amifostine; Animals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Jejunum; Mice; Mice, Inbred C3H; Radiation-Protective Agents; Radiation-Sensitizing Agents; Whole-Body Irradiation | 2001 |
The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro.
Topics: Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Humans; Lethal Dose 50; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2003 |
The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study.
Topics: Amifostine; Animals; Colitis; Collagen; Combined Modality Therapy; Cystitis; Deoxycytidine; Fibrosis; Gemcitabine; Male; Neoplasm Staging; Pelvic Neoplasms; Radiation-Protective Agents; Radiotherapy Dosage; Rats; Rats, Wistar; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2009 |